Navigation Links
BiOptix to highlight new 404pi instrument at European symposia
Date:11/1/2012

BOULDER, Colo., AMSTERDAM and VIENNA, Nov. 1, 2012 /PRNewswire/ -- BiOptix today announced that it would be highlighting the new BiOptix 404pi, the first commercially available SPR instrument to incorporate phase-based common path interferometry technology, at the Label Free Technologies Show in Amsterdam from November 1 - 3 as well as at the PEGS Europe Summit on November 6 – 8. 

"At the Label Free and PEGS Europe meetings, BiOptix will unveil new application data that demonstrates the value proposition of the upcoming BiOptix 404pi," noted Ken Wilczek, Vice President of Sales & Marketing for BiOptix.  "We are excited to demonstrate how BiOptix Enhanced or Phase-based SPR differs from standard surface plasmon resonance detection methods in that BiOptix technology combines the high sensitivity of SPR with the high stability and lower noise of common path interferometry—utilizing an internal reference for increased sensitivity."

BiOptix technology allows for the simultaneous monitoring of multiple analytes in a single sample.  This new class of SPR instrumentation from BiOptix has been designed to measure protein/protein and protein-small molecule interactions (down to 100 Da) in a high-throughput 96/384 well platform utilizing 4 parallel channels rather than a single flow cell.     

Surface Plasmon Resonance is an advanced and highly sensitive optical technology that can measure refractive index changes on a sensor chip's gold surface due to a change in mass that occurs during a binding event. This change can be used to monitor biological interactions such as the concentration of target molecules, kinetic rates and affinity constants. BiOptix has developed and patented a novel ultra-sensitive detection platform known as Enhanced Surface Plasmon resonance, or ESPR. Unlike traditional SPR, ESPR instrumentation from BiOptix enables the high sensitivity of SPR with the high stability and lower noise of common path interferometry.

About BiOptix

BiOptix Diagnostics Corporation is a privately held firm based in Boulder, Colorado, with leading investments from Boulder Ventures and Rusnano.  BiOptix has developed a new class of analytical biosensor instrumentation utilizing a patented high-throughput label-free technology known as ESPR – Enhanced Surface Plasmon Resonance. BiOptix instrumentation allows researchers to study label-free protein-protein and protein-small molecule interaction—with high sensitivity and high throughput. Applications include: Protein-small molecule interactions, protein-protein kinetics, antibody affinities and epitope mapping, oligosaccharide characterization, nucleic acid (DNA-DNA or DNA-RNA) hybridization and biomolecule concentration measurements. Additional information about BiOptix and our products can be found at:  www.bioptix.com


'/>"/>
SOURCE BiOptix
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. BiOptix Participates in Leading Life Sciences Event BioWest 2012
2. BiOptix announces expansion of Board of Directors
3. AGU journal highlights -- 31 August 2012
4. Biomass characterization technology research highlighted in Industrial Biotechnology journal
5. Genetics Society of America’s GENETICS journal highlights for August 2012
6. AGU journal highlights -- 31 July 2012
7. New video series highlights the people who fuel Americas innovation pipeline
8. AGU Journal highlights -- July 16
9. Differences between human twins at birth highlight importance of intrauterine environment
10. Genetics Society of Americas Genetics journal highlights for July 2012
11. Highlighting molecular clues to the link between childhood maltreatment and later suicide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2017)... , June 15, 2017  IBM (NYSE: IBM ) is ... tech event dedicated to developing collaboration between startups and global ... June 15-17. During the event, nine startups will showcase the ... in various industries. France ... international market, with a 30 percent increase in the number ...
(Date:5/16/2017)...  Veratad Technologies, LLC ( www.veratad.com ), an innovative ... verification solutions, announced today they will participate as a ... thru May 17, 2017, in Washington D.C.,s ... Identity impacts the lives of billions ... evolving digital world, defining identity is critical to nearly ...
(Date:5/6/2017)... , May 5, 2017 ... just announced a new breakthrough in biometric authentication ... exploits quantum mechanical properties to perform biometric authentication. These ... smart semiconductor material created by Ram Group and ... finance, entertainment, transportation, supply chains and security. Ram ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... 11, 2017 , ... The CRISPR-Cas9 system has ... and avoiding the use of exogenous expression plasmids. The simplicity of programming this ... gain-of-function studies. , This complement to loss-of-function studies, such as with RNAi ...
(Date:10/11/2017)... , Oct. 11, 2017  VMS BioMarketing, a leading provider ... nationwide oncology Clinical Nurse Educator (CNE) network, which will launch ... for communication among health care professionals to enhance the patient ... office staff, and other health care professionals to help women ... cancer. ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator ... osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular STAT3 ...
(Date:10/10/2017)... ... ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, Inc. spent ... entitled “Stem Cells and Their Regenerative Powers,” was held on August 31st, 2017 ... joined by two human doctors: Peter B. Hanson, M.D., Chief of Orthopedic Surgery, Grossmont ...
Breaking Biology Technology: